Compare Futu Holdings Ltd (FUTU) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Johnson & Johnson — how do they compare? Futu Holdings Ltd trades at $110.71 (market cap $15.25B), while Johnson & Johnson trades at $256.11 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 40.5× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Johnson & Johnson for 129 Days on average.
| FUTU | JNJ | |
|---|---|---|
Market Cap | $15.25B | $618.09B |
Volume | 812,567 | 6,050,983 |
Sector | Financials | Health |
52-Week High | $199.04 | $278.43 |
52-Week Low | $89.76 | $186.00 |
Typical Hold Time | 34 Days | 129 Days |
Enterprise Value | $15.59B | $646.37B |
Dividend Yield | 2.39% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $109.68, down 3.12% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $22.85B in 2025 with a net income margin of 49.62%, while valuation ratios like a P/E of 10.95 suggest potential undervaluation. Recent news includes Moomoo's partnership with X and a class action lawsuit deadline, adding mixed sentiment.
The outlook is cautiously optimistic due to robust earnings growth and analyst upside targets near 33%, but risks from legal issues and competitive pressures warrant monitoring. Investors may find value if the company executes on overseas expansion, though volatility from technical bearishness persists.
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
